RxDoctor Payments Data

David Levi, MD

Pain Medicine · Newtown, CTNPI 1518955236

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Boston Scientific at 34.0% of the total. Reporting peaked in 2019 at $1,112 and has fallen 73.7% since, to $293 in 2025.

$4,845in general payments, 2019–2025

Across 258 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$505
  • Collegium Pharmaceutical, Inc.$419
  • Scilex Pharmaceuticals Inc.$418
  • AbbVie$376
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$241
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,61995%
  • Education$2265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,845 in reported general payments places this provider in the 70th percentile of 69 pain medicine providers in Connecticut.

See all pain medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$496,225
Medicare patients
651
Services billed
8,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl67$39,490
Xtampza ErOxycodone Myristate15$11,066
Lidocaine122$9,207
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen395$6,431
Buprenorphine36$6,374
Oxycodone Hcl428$6,176
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen317$5,374
Cyclobenzaprine Hcl77$4,897
MovantikNaloxegol Oxalate15$4,810
Fentanyl46$3,981
Morphine Sulfate ErMorphine Sulfate157$3,425
Gabapentin266$3,335
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$2,512
Pregabalin106$2,154
Hydromorphone Hcl129$1,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$419$11,06615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 69 pain medicine providers in Connecticut.

Other pain medicine in Newtown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →